Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu1, William T Barry2, Michael Birrer3, Jung-Min Lee4, Ronald J Buckanovich5, Gini F Fleming6, BJ Rimel7, Mary K Buss8, Sreenivasa Nattam9, Jean Hurteau10, Weixiu Luo2, Philippa Quy1, Christin Whalen1, Lisa Obermayer1, Hang Lee11, Eric P Winer1, Elise C Kohn4,12, S Percy Ivy12, Ursula A Matulonis1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
3Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA
4Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
5Department of Medical Oncology, University of Michigan, Ann Arbor, MI, USA
6Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA
7Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
8Division of Hematology/Oncology, Beth-Israel Deaconess Medical Center, Boston, MA, USA
9Department of Oncology, Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN, USA
10Division of Gynecologic Oncology, North Shore University Health System, Evanston Hospital, Evanston, IL, USA
11Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA
12Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Oncology
Tập 15
1207-1214
Thông tin tác giả